AB-101 is currently in a Ph1 clinical trial to evaluate the safety and anti-tumor activity alone and in combination with rituximab in patients with relapsed or refractory NHL (ClinicalTrials.gov: NCT04673617). Ethics Approval All animal work was conducted under reviewed IACUC protocol and with ...
, a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101. AB-101 is a non-...
Artiva is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas and is also combining AB-101 with Affimed N.V.’s Innate Cell Engager AFM13 for the treatment of patients with relapsed/refractory CD...
CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation. In extensive preclinical and early clinical studies, this distinctive, multifaceted approach has been shown to inhibit
Trial Status: As of Apr 20, 2023, part A has been completed; part B is ongoing. back
and MSigDB (https://doi.org/10.1093/bioinformatics/btr260). In addition, subject to certain criteria, conditions and exceptions, Pfizer will also provide access to related individual anonymized participant data. Seehttps://www.pfizer.com/science/clinical-trials/trial-data-and-results/for more info...
Topline results from this trial are anticipated in the latter half of 2024. “These posters, which add to the preclinical evidence supporting CM-101’s potential as an effective therapy for PSC, are encouraging as we look fo...
2.Study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL with KMT2A/ MLL1r, NPM1 and other mutations. ClinicalTrials.gov. Updated October 26, 2022. Accessed November 1, 2022. https://c...
Regeneron and ISA will share clinical trial costs and exchange product supply. In addition, Regeneron will provide an upfront payment and an equity investment in exchange for an option to an exclusive, global license for ISA101. If Regeneron exercises its option to commercialize ISA101, there is...
(Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its late breaking abstract discussing the results of the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) has been selected for an...